Actively Recruiting
A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
Led by Sanguine Biosciences · Updated on 2024-12-06
20000
Participants Needed
1
Research Sites
222 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To collect, preserve, and distribute annotated leukopak biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions. This protocol will be utilized to collect research grade products that are not meant for transfusion.
CONDITIONS
Official Title
A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Persons aged 18 to 89 years at the date of informed consent
- Persons healthy enough for the apheresis procedure
- Minimum weight of 110 pounds
- Pulse between 50 and 110 beats per minute
- Blood pressure with diastolic between 50 and 100 mmHg and systolic between 90 and 180 mmHg
- Adequate peripheral venous access for apheresis as determined by staff
- Negative test results for Hepatitis B, Hepatitis C, and HIV 1-2 within 30 days, unless collecting based on these diagnoses
- Complete blood count results within site-specific parameters within 30 days of apheresis
- Ability to understand study procedures and provide written informed consent including authorization for protected health information disclosure
You will not qualify if you...
- Persons younger than 18 or older than 89 years at the date of informed consent
- History of conditions incompatible with safe apheresis as determined by medical evaluation
- Receipt of blood transfusion within 30 days before the study procedure
- Receipt of investigational (unapproved) drugs within 30 days before the study procedure
- Confirmed diagnosis of severe or untreated cardiovascular, kidney, liver, or lung diseases precluding apheresis
- Bleeding disorders, chronic anemia, active systemic infection
- Use of ACE inhibitors unless they can be safely withheld 24 hours prior to apheresis
- Pregnancy
- Donated blood within the last 2 months at the date of informed consent
- Unable to understand study procedures to provide informed consent
- Requires a legally authorized representative for study consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sanguine Biosciences
Waltham, Massachusetts, United States, 02451
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here